1.Analysis of Response and Progression Patterns of Tyrosine Kinase Inhibitors in Recurrent or Metastatic Adenoid Cystic Carcinoma: A Post Hoc Analysis of Two KCSG Phase II Trials
Youjin KIM ; Bhumsuk KEAM ; Eun Joo KANG ; Jin-Soo KIM ; Hye Ryun KIM ; Keun-Wook LEE ; Jung Hye KWON ; Kyoung Eun LEE ; Yaewon YANG ; Yoon Hee CHOI ; Min Kyoung KIM ; Jun Ho JI ; Tak YUN ; Moon Young CHOI ; Ki Hyeong LEE ; Sung-Bae KIM ; Myung-Ju AHN
Cancer Research and Treatment 2024;56(4):1068-1076
Purpose:
In this study, we evaluated 66 patients diagnosed with adenoid cystic carcinoma (ACC) enrolled in two Korean Cancer Study Group trials to investigate the response and progression patterns in recurrent and/or metastatic ACC treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs).
Materials and Methods:
We evaluated 66 patients diagnosed with ACC who were enrolled in the Korean Cancer Study Group trials. The tumor measurements, clinical data, treatment outcomes, and progression patterns of therapy were analyzed.
Results:
In the 66 patients (53 receiving axitinib and 13 receiving nintedanib), the disease control rate was 61%, and three patients achieved partial response. The median follow-up, median progression-free survival (PFS), overall survival, and 6-month PFS rate were 27.6%, 12.4%, and 18.1% months and 62.1%, respectively. Among 42 patients who experienced progression, 27 (64.3%) showed target lesion progression. Bone metastasis was an independent poor prognostic factor.
Conclusion
Overall, most patients demonstrated stable disease with prolonged PFS; however, prominent target lesion progression occurred in some patients. Thus, PFS may capture VEGFR-TKI efficacy better than the objective response rate.
3.Use of Antibiotics Within the Last 14 Days of Life in Korean Patients:A Nationwide Study
Yu Mi WI ; Ki Tae KWON ; Soyoon HWANG ; Sohyun BAE ; Yoonjung KIM ; Hyun-Ha CHANG ; Shin-Woo KIM ; Hae Suk CHEONG ; Shinwon LEE ; Dong Sik JUNG ; Kyung Mok SOHN ; Chisook MOON ; Sang Taek HEO ; Bongyoung KIM ; Mi Suk LEE ; Jian HUR ; Jieun KIM ; Young Kyung YOON ; And Antimicrobial Stewardship Research Committee of Korean Society for Antimicrobial Therapy
Journal of Korean Medical Science 2023;38(9):e66-
Background:
Antimicrobial prescriptions for serious chronic or acute illness nearing its end stages raise concerns about the potential for futile use, adverse events, increased multidrugresistant organisms, and significant patient and social cost burdens. This study investigated the nationwide situation of how antibiotics are prescribed to patients during the last 14 days of life to guide future actions.
Methods:
This nationwide multicenter retrospective cohort study was conducted at 13 hospitals in South Korea from November 1 to December 31, 2018. All decedents were included in the study. Antibiotic use during the last two weeks of their lives was investigated.
Results:
A total of 1,201 (88.9%) patients received a median of two antimicrobial agents during the last two weeks of their lives. Carbapenems were prescribed to approximately half of the patients (44.4%) in the highest amount (301.2 days of therapy per 1,000 patient-days).Among the patients receiving antimicrobial agents, 63.6% were inappropriate and only 327 patients (27.2%) were referred by infectious disease specialists. The use of carbapenem (odds ratio [OR], 1.51; 95% confidence interval [CI], 1.13–2.03; P = 0.006), underlying cancer (OR, 1.56; 95% CI, 1.20–2.01, P = 0.047), underlying cerebrovascular disease (OR, 1.88; 95% CI, 1.23–2.89, P = 0.004), and no microbiological testing (OR, 1.79; 95% CI, 1.15–2.73; P = 0.010) were independent predictors for inappropriate antibiotic prescribing.
Conclusion
A considerable number of antimicrobial agents are administered to patients with chronic or acute illnesses nearing their end-of-life, a high proportion of which are prescribed inappropriately. Consultation with an infectious disease specialist, in addition to an antimicrobial stewardship program, may be necessary to induce the optimal use of antibiotics.
4.Guidelines for the Laboratory Diagnosis of Monkeypox in Korea
Ki Ho HONG ; Gab Jung KIM ; Kyoung Ho ROH ; Hyukmin LEE ; Ok Kyu PARK ; Taek Soo KIM ; Jae-Seok KIM ; Jaehyeon LEE ; Moon-Woo SEONG ; So Yeon KIM ; Jae-Sun PARK ; Younhee PARK ; Hee Jae HUH ; Namhee RYOO ; Hyun Soo KIM ; Heungsup SUNG ; Cheon Kwon YOO ;
Annals of Laboratory Medicine 2023;43(2):137-144
While the coronavirus disease 2019 pandemic is ongoing, monkeypox has been rapidly spreading in non-endemic countries since May 2022. Accurate and rapid laboratory tests are essential for identifying and controlling monkeypox. Korean Society for Laboratory Medicine and the Korea Disease Prevention and Control Agency have proposed guidelines for diagnosing monkeypox in clinical laboratories in Korea. These guidelines cover the type of tests, selection of specimens, collection of specimens, diagnostic methods, interpretation of test results, and biosafety. Molecular tests are recommended as confirmatory tests. Skin lesion specimens are recommended for testing in the symptomatic stage, and the collection of both blood and oropharyngeal swabs is recommended in the presymptomatic or prodromal stage.
5.Coronary Artery Calcium Score as a Sensitive Indicator of Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus: A Long-Term Cohort Study
Dae-Jeong KOO ; Mi Yeon LEE ; Sun Joon MOON ; Hyemi KWON ; Sang Min LEE ; Se Eun PARK ; Cheol-Young PARK ; Won-Young LEE ; Ki Won OH ; Sung Rae CHO ; Young-Hoon JEONG ; Eun-Jung RHEE
Endocrinology and Metabolism 2023;38(5):568-577
Background:
Coronary artery calcium score (CACS) has become an important tool for evaluating cardiovascular disease (CVD). This study evaluated the significance of CACS for future CVD through more than 10 years of follow-up in asymptomatic Korean populations with type 2 diabetes mellitus (T2DM) known to have a relatively low CACS burden.
Methods:
We enrolled 981 asymptomatic T2DM patients without CVD at baseline who underwent CACS evaluation using multidetector computed tomography between January 2008 and December 2014. They were grouped into five predefined CACS categories based on Agatston scores and followed up by August 2020. The primary endpoint was incident CVD events, including coronary, cerebrovascular, and peripheral arterial disease.
Results:
The relative risk of CVD was significantly higher in patients with CACS ≥10, and the significance persisted after adjustment for known confounders. A higher CACS category indicated a higher incidence of future CVD: hazard ratio (95% confidence interval) 4.09 (1.79 to 9.36), 12.00 (5.61 to 25.69), and 38.79 (16.43 to 91.59) for 10≤ CACS <100, 100≤ CACS <400, and CACS ≥400, respectively. During the 12-year follow-up period, the difference in event-free survival more than doubled as the category increased. Patients with CACS below 10 had very low CVD incidence throughout the follow-up. The receiver operating characteristic analysis showed better area under curve when the CACS cutoff was 10 than 100.
Conclusion
CACS can be a sensitive marker of CVD risk. Specifically, CACS above 10 is an indicator of CVD high-risk requiring more intensive medical treatment in Koreans with T2DM.
6.Core Elements for Implementing Antimicrobial Stewardship Programs in Korean General Hospitals
Hae Suk CHEONG ; Kyung-Hwa PARK ; Hong Bin KIM ; Shin-Woo KIM ; Bongyoung KIM ; Chisook MOON ; Mi Suk LEE ; Young Kyung YOON ; Su Jin JEONG ; Yong Chan KIM ; Byung Wook EUN ; Hyukmin LEE ; Ji-Yeon SHIN ; Hyung-sook KIM ; In Sun HWANG ; Choon-Seon PARK ; Ki Tae KWON ; Korean Society for Antimicrobial Therapy, The Korean Society of Infectious Diseases, Korean Society
Infection and Chemotherapy 2022;54(4):637-673
Currently, antimicrobial resistance (AMR) is a major threat to global public health. The antimicrobial stewardship program (ASP) has been proposed as an important approach to overcome this crisis. ASP supports the optimal use of antimicrobials, including appropriate dosing decisions, administration duration, and administration routes. In Korea, efforts are being made to overcome AMR using ASPs as a national policy. The current study aimed to develop core elements of ASP that could be introduced in domestic medical facilities. A Delphi survey was conducted twice to select the core elements through expert consensus.The core elements for implementing the ASP included (1) leadership commitment, (2) operating system, (3) action, (4) tracking, (5) reporting, and (6) education. To ensure these core elements are present at medical facilities, multiple departments must collaborate as teams for ASP operations. Establishing a reimbursement system and a workforce for ASPs are prerequisites for implementing ASPs. To ensure that ASP core elements are actively implemented in medical facilities, it is necessary to provide financial support for ASPs in medical facilities, nurture the healthcare workforce in performing ASPs, apply the core elements to healthcare accreditation, and provide incentives to medical facilities by quality evaluation criteria.
7.Korean Guidelines for Use of Antibiotics for Intra-abdominal Infections in Adults
Young Kyung YOON ; Chisook MOON ; Jieun KIM ; Sang Taek HEO ; Mi Suk LEE ; Shinwon LEE ; Ki-Tae KWON ; Shin-Woo KIM ; Korean Society for Antimicrobial Therapy and Korean Society of Infectious Diseases
Infection and Chemotherapy 2022;54(4):812-853
The guidelines are intended to provide practical information for the correct use of antibiotics for intra-abdominal infections in Korea. With the aim of realizing evidence-based treatment, these guidelines for the use of antibiotics were written to help clinicians find answers to key clinical questions that arise in the course of patient care, using the latest research results based on systematic literature review. The guidelines were prepared in consideration of the data on the causative pathogens of intra-abdominal infections in Korea, the antibiotic susceptibility of the causative pathogens, and the antibiotics available in Korea.
8.Impact of Pediatric Alopecia Areata on Quality of Life of Patients and Their Family Members: A Nationwide Multicenter Questionnaire Study
Jee Woong CHOI ; Yul Hee KIM ; Hyunbin KWAK ; Jin PARK ; Won-Soo LEE ; Hoon KANG ; Jung Eun KIM ; Tae-Young YOON ; Ki-Ho KIM ; Yong Hyun JANG ; Do Won KIM ; Moon-Bum KIM ; Bark-Lynn LEW ; Woo-Young SIM ; Jiehyun JEON ; Soo Hong SEO ; Ohsang KWON ; Chang-Hun HUH ; Dong-Youn LEE ; Yang Won LEE ; Byung Choel PARK ; Chong Hyun WON ; Do Young KIM ; Hyojin KIM ; Beom Joon KIM ; Young LEE ; Sang Seok KIM ; Gwang Seong CHOI ; The Korean Hair Research Society
Annals of Dermatology 2022;34(4):237-244
Background:
Pediatric alopecia areata (AA) can affect the quality of life (QoL) of patients and their family members. Research on the QoL and burden on family members in pediatric AA is limited.
Objective:
This nationwide multicenter questionnaire study described the QoL and burden of the family members of patients with pediatric AA.
Methods:
This nationwide multicenter questionnaire study enrolled AA patients between the ages of 5 and 18 years from March 1, 2017 to February 28, 2018. Enrolled patients and their parents completed the modified Children’s Dermatology Life Quality Index (CDLQI) and the modified Dermatitis Family Impact (mDFI). The disease severity was measured using the Severity of Alopecia Tool (SALT) survey scores.
Results:
A total of 268 patients with AA from 22 hospitals participated in this study. Our study found that the efficacy and satisfaction of previous treatments of AA decreased as the severity of the disease increased. The use of home-based therapies and traditional medicines increased with the increasing severity of the disease, but the efficacy felt by patients was limited. CDLQI and mDFI scores were higher in patients with extensive AA than those with mild to moderate AA. The economic and time burden of the family members also increased as the severity of the disease increased.
Conclusion
The severity of the AA is indirectly proportional to the QoL of patients and their family members and directly proportional to the burden. Physicians need to understand these characteristics of pediatric AA and provide appropriate intervention to patients and their family members.
9.Prasugrel-based De-Escalation of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With STEMI
You-Jeong KI ; Bong Ki LEE ; Kyung Woo PARK ; Jang-Whan BAE ; Doyeon HWANG ; Jeehoon KANG ; Jung-Kyu HAN ; Han-Mo YANG ; Hyun-Jae KANG ; Bon-Kwon KOO ; Dong-Bin KIM ; In-Ho CHAE ; Keon-Woong MOON ; Hyun Woong PARK ; Ki-Bum WON ; Dong Woon JEON ; Kyoo-Rok HAN ; Si Wan CHOI ; Jae Kean RYU ; Myung Ho JEONG ; Kwang Soo CHA ; Hyo-Soo KIM ; On behalf of the HOST-RP-ACS investigators
Korean Circulation Journal 2022;52(4):304-319
Background and Objectives:
De-escalation of dual-antiplatelet therapy through dose reduction of prasugrel improved net adverse clinical events (NACEs) after acute coronary syndrome (ACS), mainly through the reduction of bleeding without an increase in ischemic outcomes. Whether the benefits of de-escalation are sustained in highly thrombotic conditions such as ST-elevation myocardial infarction (STEMI) is unknown. We aimed to assess the efficacy and safety of de-escalation therapy in patients with STEMI or non-STsegment elevation ACS (NSTE-ACS).
Methods:
This is a pre-specified subgroup analysis of the HOST-REDUCE-POLYTECH-ACS trial. ACS patients were randomized to prasugrel de-escalation (5 mg daily) or conventional dose (10 mg daily) at 1-month post-percutaneous coronary intervention. The primary endpoint was a NACE, defined as a composite of all-cause death, non-fatal myocardial infarction, stent thrombosis, clinically driven revascularization, stroke, and bleeding events of grade ≥2 Bleeding Academic Research Consortium (BARC) criteria at 1 year.
Results:
Among 2,338 patients included in the randomization, 326 patients were diagnosed with STEMI. In patients with NSTE-ACS, the risk of the primary endpoint was significantly reduced with de-escalation (hazard ratio [HR], 0.65; 95% confidence interval [CI], 0.48– 0.89; p=0.006 for de-escalation vs. conventional), mainly driven by a reduced bleeding. However, in those with STEMI, there was no difference in the occurrence of the primary outcome (HR, 1.04; 95% CI, 0.48–2.26; p=0.915; p for interaction=0.271).
Conclusions
Prasugrel dose de-escalation reduced the rate of NACE and bleeding, without increasing the rate of ischemic events in NSTE-ACS patients but not in STEMI patients.
10.Erratum: Correction of Text in the Article “Prasugrel-based De-Escalation of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With STEMI”
You-Jeong KI ; Bong Ki LEE ; Kyung Woo PARK ; Jang-Whan BAE ; Doyeon HWANG ; Jeehoon KANG ; Jung-Kyu HAN ; Han-Mo YANG ; Hyun-Jae KANG ; Bon-Kwon KOO ; Dong-Bin KIM ; In-Ho CHAE ; Keon-Woong MOON ; Hyun Woong PARK ; Ki-Bum WON ; Dong Woon JEON ; Kyoo-Rok HAN ; Si Wan CHOI ; Jae Kean RYU ; Myung Ho JEONG ; Kwang Soo CHA ; Hyo-Soo KIM ;
Korean Circulation Journal 2022;52(6):483-484

Result Analysis
Print
Save
E-mail